Status:

COMPLETED

Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism

Lead Sponsor:

Gyeongsang National University Hospital

Conditions:

Myocardial Infarction

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Percutaneous coronary intervention (PCI) with stent implantation is the preferred reperfusion strategy for treatment of acute myocardial infarction (AMI). Despite advances in both devices and pharmaco...

Detailed Description

* Study timeline: Enrollment period - 6 months (2009. 5.- 2009. 10.) (Follow-up period - 1 month after randomization) * Stenting, adjunct drug therapy and markers of myonecrosis 1\) PCI (...

Eligibility Criteria

Inclusion

  • The patient must be at least 18 years of age.
  • clinical symptoms compatible with acute myocardial ischemia within 12 h before admission with a subsequently documented increase in cardiac markers.
  • Measured pre-discharge platelet reactivity in case of normalized CK-MB value after coronary stenting.

Exclusion

  • A history of active bleeding and bleeding diatheses.
  • Oral anticoagulation therapy with coumadin.
  • Contraindication to antiplatelet therapy.
  • LV ejection fraction \< 30% or NYHA 3/4.
  • Leukocyte count \< 3,000/mm3 and/or platelet count \< 100,000/mm3.
  • AST or ALT ≥ 3 times upper normal.
  • Serum creatinine level ≥ 2.5 mg/dl.
  • Stroke within 3 months.
  • Non-cardiac disease with a life expectancy \< 1 year.
  • Inability to follow the protocol.

Key Trial Info

Start Date :

May 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2009

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT00915733

Start Date

May 1 2009

End Date

November 1 2009

Last Update

November 10 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gyeongsang National University Hospital

Jinju, South Korea, 660-702